A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Incyte Corporation
BerGenBio ASA
Memorial Sloan Kettering Cancer Center
Quadriga Biosciences, Inc.
Xencor, Inc.
Incyte Corporation
AbbVie
Incyte Corporation
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Swiss Cancer Institute
Novartis
GOG Foundation
Children's Oncology Group
INSYS Therapeutics Inc
University of Chicago
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)